OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility
This article was originally published in The Pink Sheet
Executive Summary
Changes to FDA's interpretation of the GRASE standard it uses to evaluate ingredient proposals would go further to opening the US monograph process to innovation and progress than setting deadlines for the reviews, industry stakeholders say.
You may also be interested in...
FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review
The agency maintains maximal usage trials are essential in sunscreen ingredient GRASE assessments, despite industry objections that the tests have not been used for UV filters and no protocol is established. FDA’s final guidance closely mirrors its draft issued a year ago, which stakeholders projected would further delay consumer access to updated sunscreen products.
FDA Adds OTC Monograph Staff By Shifting CDER Appropriations
CDER will add five staff members to expand to 23 the number committed to working on the monograph program, an unexpected development for the OTC industry especially in light of FDA's proposals for monograph program user fee.
FDA Proposes Illuminating OTC Monograph Process With Sunscreen TEA Framework
A proposed rule that sets deadlines for multiple steps in its reviews of TEAs for OTC ingredients should make the monograph process more transparent to the industry, but a timeline for sunscreen ingredient TEAs, as required by the Sunscreen Innovation Act, has not opened a door on application approvals.